


New research identifies three distinct multiple sclerosis endophenotypes for personalized treatment

April 4 2024



Heinz Wiendl, Luisa Klotz and Andreas Schulte-Mecklenbeck from the University of Münster performed high-dimensional flow cytometry to describe MS in unprecedented detail. Credit: Uni MS/Wibberg



In a transformative study <u>published</u> in the journal *Science Translational Medicine*, an international team of researchers has made a significant breakthrough in the understanding and potential treatment of multiple sclerosis (MS).

Their findings reveal the identification of three distinct immunological endophenotypes of MS, defined by specific blood immune signatures associated with different disease trajectories. This discovery opens new avenues for personalized <u>treatment strategies</u>, addressing the long-standing challenge of individualized <u>treatment selection</u> in MS therapy.

MS is a complex and unpredictable disease, affecting more than 2.8 million people worldwide. It has long been recognized for its varied clinical manifestations and progression, making effective treatment a significant challenge. Traditional approaches to treatment have often been a one-size-fits-all solution, not taking into account the underlying distinct immunopathology prevailing in each patient.

The study, which analyzed data from over 500 early MS patients across two independent cohorts, utilized high-dimensional flow cytometry and serum proteomics to map the immune system's complexity in unprecedented detail. The researchers' sophisticated analysis identified three distinct immunological endophenotypes, each associated with specific disease pathways and responses to treatment.

"These findings represent a pivotal shift towards <u>precision medicine</u> in MS," stated Prof. Heinz Wiendl, one of the lead authors of the study. "By understanding the individual immune system variations among patients, we can move closer to personalized treatment plans that are



more effective and have fewer side effects."

The endophenotypes, named based on their primary characteristics—"inflammatory," "degenerative," and a third yet to be fully characterized—show distinct responses to common MS treatments. Notably, patients within the 'inflammatory' endophenotype showed limited benefit from interferon-beta treatment, suggesting that alternative therapies might be more effective for this group.

"Our study not only challenges the current treatment paradigm but also helps to provide a practical tool for clinicians to predict <u>disease</u> <u>progression</u> and treatment response," added Prof. Luisa Klotz, co-lead author. "This could significantly improve the quality of life for individuals living with MS."

Further, the study highlighted the potential for using these endophenotypes as markers for disease prognosis and treatment efficacy. This insight could guide the development of new therapeutic agents targeted at specific pathways within these endophenotypes.

The findings have been welcomed by the neurology and neuroimmunology communities as a major step forward in the fight against MS. They underscore the importance of individualized care and the potential for significantly improving treatment outcomes by tailoring therapies to the patient's specific immune signature.

The research was led by the University of Münster and Department of Neurology at the University Hospital of Münster, Germany, in collaboration with the German Competence Network Multiple Sclerosis (KKNMS).

More information: Catharina C. Gross et al, Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are



associated with distinct disease trajectories, *Science Translational Medicine* (2024). DOI: 10.1126/scitranslmed.ade8560

Provided by University of Münster

Citation: New research identifies three distinct multiple sclerosis endophenotypes for personalized treatment (2024, April 4) retrieved 21 May 2024 from https://medicalxpress.com/news/2024-04-distinct-multiple-sclerosis-endophenotypes-personalized.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.